Additional file 3 of Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy

Additional file 3: Table 2. Disease status and treatment outcomes at CART2.-: no follow-up. *, MRD-negative CR was obtained after chemotherapy. CART2 was performed to prevent a recurrence. #, Pt01 relapsed after CART2 and received a third CAR-T salvage therapy. + : On the fourth day after CART2 reinfusion, pt04 began to develop testicular edema, along with redness and pain. After a week, the mass gradually shrank, and the tissue returned to normal size.